Celltrion says trial shows antibody COVID-19 treatment to be safe and effective

Celltrion

14/06/2021 02:42

By Sangmi Cha
    SEOUL, June 14 (Reuters) - South Korean drugmaker Celltrion
Inc  068270.KS  on Monday announced positive results for its
experimental antibody COVID-19 treatment that it said was safe
and reduced the treatment period by nearly five days in Phase 3
global clinical trials.
    The trials, which involved 1,315 participants, have taken
place since January in 13 countries, including in South Korea,
the United States, Spain and Romania, Celltrion said in a
statement. 
    The treatment slowed severe symptoms of COVID-19 in more
than 70% of patients, including the high-risk group with
underlying conditions. It also cut the recovery period by 4.9
days, the company said.
    In February South Korea, granted conditional approval to the
antibody treatment, making it the first locally made coronavirus
treatment in the country to win such approval. The company said
it would seek full authorization based on the trial results. 
    Celltrion shares rose as much as 5.6% in Monday morning
trade, compared with a 0.3% drop in the wider market  .KS11 . 
    

 (Reporting by Sangmi Cha, additional reporting by Joyce Lee.
Editing by Gerry Doyle)
 ((sangmi.cha@thomsonreuters.com;))